Chemical compound
Azatadine (Optimine) is a first-generation antihistamine and anticholinergic drug that was synthesized in 1963 by Schering-Plough, a former American pharmaceutical company.[1][2]
It was patented in 1967.[3] It has been succeeded by both loratadine and desloratadine.[4]: 53 and marketing approvals have been widely withdrawn.[5][6][7][8]: 290 [9]
See also
References
- ^ Katelaris C (December 1990). "Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis". Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–7. PMID 1982614.
- ^ Small P, Barrett D, Biskin N (February 1990). "Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation". Annals of Allergy. 64 (2 Pt 1): 129–31. PMID 1968324.
- ^ US 3326924, Villani FJ, Caldwell W, "Azatadine", issued 1967
- ^ Horak F (2010). "Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4". In Pawankar R, Holgate ST, Rosenwasser LJ (eds.). Allergy Frontiers:Therapy and Prevention. Vol. 5. Springer Science & Business Media. ISBN 9784431993629.
- ^ "Azatadine". Drugs.com.
- ^ Food and Drug Administration (2005). "Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications". Federal Register 70 FR 10651.
- ^ Food and Drug Administration (2007). "Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions". Federal Register 72 FR 8184.
- ^ "Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals" (PDF). Department of Economic and Social Affairs of the United Nations Secretariat. New York: United Nations. 2005.
- ^ "OGD Suitability Tracking Report (Sorted by Drug Name)". FDA.